1. Home
  2. IMCR vs DOLE Comparison

IMCR vs DOLE Comparison

Compare IMCR & DOLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMCR
  • DOLE
  • Stock Information
  • Founded
  • IMCR 2008
  • DOLE 1851
  • Country
  • IMCR United Kingdom
  • DOLE Ireland
  • Employees
  • IMCR N/A
  • DOLE N/A
  • Industry
  • IMCR Biotechnology: Biological Products (No Diagnostic Substances)
  • DOLE Farming/Seeds/Milling
  • Sector
  • IMCR Health Care
  • DOLE Consumer Staples
  • Exchange
  • IMCR Nasdaq
  • DOLE Nasdaq
  • Market Cap
  • IMCR 1.5B
  • DOLE 1.3B
  • IPO Year
  • IMCR 2021
  • DOLE 2021
  • Fundamental
  • Price
  • IMCR $32.80
  • DOLE $14.22
  • Analyst Decision
  • IMCR Buy
  • DOLE Buy
  • Analyst Count
  • IMCR 10
  • DOLE 3
  • Target Price
  • IMCR $58.13
  • DOLE $16.67
  • AVG Volume (30 Days)
  • IMCR 444.9K
  • DOLE 631.0K
  • Earning Date
  • IMCR 08-07-2025
  • DOLE 08-13-2025
  • Dividend Yield
  • IMCR N/A
  • DOLE 2.39%
  • EPS Growth
  • IMCR N/A
  • DOLE N/A
  • EPS
  • IMCR N/A
  • DOLE 0.99
  • Revenue
  • IMCR $333,581,000.00
  • DOLE $8,453,373,000.00
  • Revenue This Year
  • IMCR $26.82
  • DOLE $3.87
  • Revenue Next Year
  • IMCR $8.15
  • DOLE $1.93
  • P/E Ratio
  • IMCR N/A
  • DOLE $11.55
  • Revenue Growth
  • IMCR 25.75
  • DOLE 0.91
  • 52 Week Low
  • IMCR $23.15
  • DOLE $12.14
  • 52 Week High
  • IMCR $41.54
  • DOLE $17.12
  • Technical
  • Relative Strength Index (RSI)
  • IMCR 51.47
  • DOLE 50.58
  • Support Level
  • IMCR $30.76
  • DOLE $13.62
  • Resistance Level
  • IMCR $33.95
  • DOLE $14.43
  • Average True Range (ATR)
  • IMCR 1.39
  • DOLE 0.27
  • MACD
  • IMCR -0.15
  • DOLE 0.04
  • Stochastic Oscillator
  • IMCR 43.05
  • DOLE 52.73

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About DOLE Dole plc

Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace.

Share on Social Networks: